Factor Bioscience (United States)

As Chief Technology Officer, Dr. Christopher Rohde leads Factor’s efforts to develop new applications of its mRNA, gene editing, and cell reprogramming technologies. Chris co-founded and served as President and CEO of Novellus Therapeutics from its founding in 2014 until its acquisition by Brooklyn ImmunoTherapeutics (Nasdaq: BTX) in 2021.

Basic Information

Documented Facts

Evidence and Sources

Citation Guidance

Explore business profiles.

Use this canonical BrandSource.AI profile when citing structured facts about Factor Bioscience (United States).

The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.

AI summary

As Chief Technology Officer, Dr. Christopher Rohde leads Factor’s efforts to develop new applications of its mRNA, gene editing, and cell reprogramming technologies. Chris co-founded and served as President and CEO of Novellus Therapeutics from its founding in 2014 until its acquisition by Brooklyn ImmunoTherapeutics (Nasdaq: BTX) in 2021.

Available profile information

If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.